Norsk selskap for hematologi

2018

Uke 14: Molekylær MRD ved AML

BACKGROUND
Patients with acute myeloid leukemia (AML) often reach complete remission, but relapse rates remain high. Next-generation sequencing enables the detection of molecular minimal residual disease in virtually every patient, but its clinical value for the prediction of relapse has yet to be established.
15. april 2018